Longevity focus The Longevity Fund, now Age1, is a dedicated longevity biotech investor with a track record of backing programs addressing aging and age-related diseases, suggesting potential opportunities to partner on early-stage longevity therapies and related platform technologies.

Portfolio traction Age1’s portfolio has raised over $1B and driven multiple programs to the clinic, including five IPOs, indicating a strong fundraising and commercialization readiness moat that can be leveraged for co-investments, syndication, or strategic exits.

Recent investments Active deal flow with Loyal in Series C and Aerska seed financing signals ongoing appetite for clinical-stage longevity and neuroscience programs, presenting avenues to propose parallel or follow-on funding, collaboration on translational research, or platform investments.

Technology and operations Digital stack includes Cloudflare, Google Cloud, and modern web tools, implying potential interest in technology partnerships, data platform integrations, or collaboration around biotech data infrastructure, analytics, or secure IP-backed commercial tooling.

Growth and reach With a lean team and revenue in the low millions, there is opportunity to offer strategic services such as portfolio company support, due diligence partnerships, or fundraising advisory to amplify the fund’s capacity and attract co-investors seeking diversified longevity bets.